推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
2-8°C
SMILES字符串
O=C1N/C(N(C(N1CC2=NN(C=N2)C)=O)CC3=CC(F)=C(F)C=C3F)=N\C4=CC5=CN(N=C5C=C4Cl)C
InChI
1S/C22H17ClF3N9O2/c1-32-7-12-4-18(13(23)5-17(12)30-32)28-20-29-21(36)35(9-19-27-10-33(2)31-19)22(37)34(20)8-11-3-15(25)16(26)6-14(11)24/h3-7,10H,8-9H2,1-2H3,(H,28,29,36)
InChI key
QMPBBNUOBOFBFS-UHFFFAOYSA-N
生化/生理作用
Orally available potent and selective noncovalent and nonpeptidic inhibitor of SARS-CoV-2 3C-like protease (3CLpro, or Mpro)
S-217622 is an orally available potent and selective noncovalent and nonpeptidic inhibitor of SARS-CoV-2 3C-like protease (3CLpro, or Mpro) that exhibits antiviral activity in vitro against varies variants of SARS-CoV-2 and other coronaviruses. S-217622 potently inhibits intrapulmonary replication of SARS-CoV-2 in mice.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
Journal of medicinal chemistry, 65(9), 6499-6512 (2022)
S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2
Tyndall JDA
Journal of Medicinal Chemistry, 65(9), 6496-6498 (2022)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门